Genus, a global leader in animal genetics, has reported a record first-half performance for FY26, with operating profits (including joint ventures) rising 40 per cent in the six months ended 31 December 2025. The results mark the strongest first-half profit delivery in the company’s history, underlining the commercial momentum of its science-led strategy.
The robust financial performance was accompanied by significant strategic progress across Genus’s livestock innovation portfolio, particularly in porcine genetics and disease resilience.
Strategic Milestones in China and Canada
During the reporting period, Genus completed a transformational porcine joint venture in China with local partner BCA, strengthening its access to the world’s largest pork market. The partnership is expected to accelerate the deployment of advanced genetics and biosecure breeding technologies across the Chinese pork sector.
In a further milestone, Genus received regulatory approval in Canada for its PRRS-resistant pig gene edit in January 2026. Porcine Reproductive and Respiratory Syndrome (PRRS) remains one of the most economically damaging diseases in global pig production, and the approval represents a major step towards commercialising disease-resistant livestock genetics.
Science-Driven Growth and Productivity Focus
Genus’s performance reflects growing demand for genetic solutions that enhance animal health, welfare and productivity, as livestock producers face rising costs, disease pressures and sustainability expectations. By integrating gene editing, advanced breeding programmes and local partnerships, the company is positioning itself at the forefront of next-generation livestock improvement.
Commenting on the results, Jorgen Kokke, Chief Executive Officer of Genus, highlighted both the financial achievement and the collaborative effort behind it. He credited teams across global markets for working closely with customers and supporting one another to deliver strong outcomes.
Implications for the Livestock and Dairy Value Chain
Although Genus’s recent milestones centre on porcine genetics, the broader implications extend across the livestock sector, including dairy. Disease resistance, genetic efficiency and animal welfare improvements are increasingly critical to sustainable protein production and long-term food security.
Genus’s record performance signals continued investor and industry confidence in science-led livestock innovation, particularly as regulatory frameworks begin to accommodate responsibly developed gene-edited traits. As pressure mounts on global food systems, the company’s progress illustrates how genetics can play a central role in improving resilience, productivity and animal wellbeing across protein value chains.
